Tapering “Transitory” & Merck’s Pill Approval - podcast episode cover

Tapering “Transitory” & Merck’s Pill Approval

Dec 01, 202139 min
--:--
--:--
Download Metacast podcast app
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more

Episode description

The markets are reacting to comments from Fed Chair Jerome Powell, who announced a plan to taper its asset purchases faster. He--and the rest of the economist community--is ready to retire the word “transitory,” but his comments have not retired questions and concerns from investors. CNBC’s Steve Liesman explains Powell’s comments. CEO of Lazard’s Financial Advisory business Peter Orszag discusses Fed leadership and Lazard’s efforts to quantify climate issues in the equities market. The FDA has narrowly endorsed Merck’s oral Covid treatment pill; former FDA Commissioner Dr. Scott Gottlieb discusses therapeutics, vaccine efficacy against the omicron variant, and Covid-19’s evolution. Plus, how much do you love Tesla? Enough for a tattoo?

 

In this episode:
Dr. Scott Gottlieb, @ScottGottliebMD

Peter Orszag, @porszag

Steve Liesman, @SteveLiesman
Joe Kernen, @JoeSquawk

Becky Quick, @BeckyQuick

Andrew Ross Sorkin, @andrewrsorkin

Katie Kramer, @Kramer_Katie


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

For the best experience, listen in Metacast app for iOS or Android